Each year in the United States, over 2.8 million antimicrobial-resistant infections occur, leading to more than 35,000 deaths, according to the CDC's Antibiotic Resistance (AR) Threats Report. This highlights the critical importance of recognizing U.S. Antibiotic Awareness Week (USAAW). The week aims to raise awareness about the responsible use of antibiotics and the increasing threat of antimicrobial resistance. #ISTX #CDC #USAAW2024
关于我们
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company developing and delivering innovative therapies in critical care and infectious disease. Our approved treatments are indicated for use in life-threatening circumstances for seriously ill patients, and our investigational therapies are in development for patients fighting drug-resistant pathogens. Growing antimicrobial resistance to existing therapies represents an urgent threat to global public health, and is directly related to significant mortality rates and longer, more expensive hospital stays. We are proud to work with physicians, nurses, hospital pharmacists and administrators, and all who devote their time to caring for patients.
- 网站
-
https://innovivaspecialtytherapeutics.com/
Innoviva Specialty Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，MA
- 类型
- 私人持股
- 创立
- 2023
- 领域
- Cardiovascular和Anti-infectives
地点
-
主要
获取路线
35 Gatehouse Drive
US，MA，Waltham，02451
Innoviva Specialty Therapeutics, Inc.员工
动态
-
This week, we invite you to support the CDC’s efforts to raise awareness about the proper use of antibiotics to help combat antibiotic resistance in the U.S. and around the world. As a leader in antibiotic drug development, we understand the importance of using existing antibiotics judiciously while also investing in the development of new therapies to address these infections. #Antimicrobialresistance, #CDC,?#USAAW2024
-
-
We are incredibly honored to have been nominated for the #PrixGalienUSA2024 “Best Biotechnology Product Award” for XACDURO?, our pathogen-targeted antibiotic against hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in adults caused by Acinetobacter baumannii. Thank you to the @Galien Foundation and the award committee for recognizing our innovation and efforts to bring XACDURO to patients. #lifesciences #healthcareinnovation #biotech
-
-
On Monday, November 4, Prix Galien USA Awards Committee members and nominees for the Prix Galien Best Biotechnology Product Award category will discuss the therapeutic and industrial challenges they faced while successfully bringing life-changing innovations to market. For more information, please visit https://lnkd.in/eUKy2V3S. #prixgalien
-
-
We are excited to announce Michalene Bauer's appointment as our new Vice President of Sales and Market Access.?Michalene’s proven leadership and therapeutic area expertise will play a pivotal role in driving awareness and access to our innovative therapeutics in critical care and infectious diseases medicine. Please join us in welcoming her to the Innoviva Specialty Therapeutics team.?
-
-
At #STS2024 we look forward to engaging healthcare professionals in insightful discussions about the use of vasopressors in the perioperative management of vasoplegic shock. Will we see you at STS Perioperative & Critical Care 2024? #STS2024 #ISTX #criticalcare
-
-
We look forward to having insightful discussions about treating dangerously low blood pressure and shock in patients during the perioperative period. Want to join the conversation? Visit us at Booth #15036 at #ANES24 this year.
-